InVitae Corp (NASDAQ: NVTA) and CareDx (NASDAQ:CDNA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.
Valuation & Earnings
This table compares InVitae Corp and CareDx’s top-line revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
CareDx has higher revenue and earnings than InVitae Corp.
Institutional & Insider Ownership
29.2% of CareDx shares are owned by institutional investors. 5.4% of CareDx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This is a summary of current recommendations and price targets for InVitae Corp and CareDx, as reported by MarketBeat.com.
||Strong Buy Ratings
InVitae Corp presently has a consensus target price of $14.33, suggesting a potential upside of 43.48%. CareDx has a consensus target price of $6.75, suggesting a potential upside of 53.06%. Given CareDx’s higher probable upside, analysts plainly believe CareDx is more favorable than InVitae Corp.
This table compares InVitae Corp and CareDx’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
CareDx beats InVitae Corp on 8 of the 10 factors compared between the two stocks.
InVitae Corp Company Profile
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company’s products consisted of assays totaling over 1,100 genes that could be used for multiple indications, including hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders and other hereditary conditions. The Company offers panels for a range of hereditary conditions in cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company focuses on genetic testing, genome network and genome management. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. The Company holds interests in AltaVoice, a patient-centered data company.
CareDx Company Profile
CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.
Receive News & Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related companies with MarketBeat.com's FREE daily email newsletter.